Cormorant Asset Management LP Sells 1,175,000 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Posted by Geri Gentry on Jun 18th, 2026

Cormorant Asset Management LP reduced its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 54.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,000,000 shares of the company’s stock after selling 1,175,000 shares during the quarter. NewAmsterdam Pharma accounts for approximately 1.6% of Cormorant Asset Management LP’s holdings, making the stock its 15th biggest position. Cormorant Asset Management LP’s holdings in NewAmsterdam Pharma were worth $35,080,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in NAMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of NewAmsterdam Pharma during the 1st quarter valued at about $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after purchasing an additional 34,563 shares during the period. Geode Capital Management LLC grew its stake in shares of NewAmsterdam Pharma by 15.9% during the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after purchasing an additional 13,629 shares during the period. Legal & General Group Plc grew its stake in shares of NewAmsterdam Pharma by 33.5% during the 2nd quarter. Legal & General Group Plc now owns 44,235 shares of the company’s stock valued at $801,000 after purchasing an additional 11,106 shares during the period. Finally, Invesco Ltd. grew its stake in shares of NewAmsterdam Pharma by 12.7% during the 2nd quarter. Invesco Ltd. now owns 134,035 shares of the company’s stock valued at $2,427,000 after purchasing an additional 15,101 shares during the period. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $869,158.57. The trade was a 72.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.74% of the stock is currently owned by insiders.

NewAmsterdam Pharma Stock Down 0.1%

NAMS stock opened at $30.15 on Thursday. NewAmsterdam Pharma Company N.V. has a twelve month low of $17.63 and a twelve month high of $42.21. The stock has a market cap of $3.52 billion, a P/E ratio of -16.84 and a beta of 0.07. The business’s 50-day moving average price is $33.26 and its 200-day moving average price is $33.42.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The company had revenue of $3.04 million for the quarter. On average, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Truist Financial assumed coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target for the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim boosted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Finally, Needham & Company LLC lifted their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $48.60.

Get Our Latest Analysis on NAMS

NewAmsterdam Pharma Company Profile

(Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.